A Phase Ib/II Study of OMP-59R5 plus Etoposide and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer

Full Title

A Phase 1b/2 Study of Tarextumab OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)


Etoposide and cisplatin are two drugs commonly used to treat extensive stage small cell lung cancer (ES-SCLC). In this study, researchers want to find the highest dose of an investigational drug called OMP-59R5 that can be given safely with etoposide and cisplatin in patients with ES-SCLC, and to evaluate the preliminary effectiveness of this drug combination.

OMP-59R5 is an antibody that binds to a particular molecule on tumor cells and may block the growth of early small cell lung cancer cells. OMP-59R5, etoposide, and cisplatin are all given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have newly diagnosed, previously untreated ES-SCLC.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Charles Rudin at 646-888-4336.